In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.

Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's learned from working in global markets, and key pipeline highlights.

Imunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.

LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous perspective on the CEO role.

Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesn't mean biopharmaceutical companies can backslide on compliance in global markets.

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.